Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study

Wolfgang Janni,Nadia Harbeck,Brigitte Rack,D Augustin,J Jueckstock,Arthur Wischnik,K Annecke,Christoph Scholz,J Huober,Thomas Zwingers,Thomas W. P. Friedl,Marion Kiechle

Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study

2016

Wolfgang Janni
Nadia Harbeck
Brigitte Rack
D Augustin
J Jueckstock
Arthur Wischnik
K Annecke
Christoph Scholz
J Huober
Thomas Zwingers
Thomas W. P. Friedl
Marion Kiechle

Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study

Keywords:

Breast cancer
Fluorouracil
Epirubicin
Axilla
Survival analysis
Medicine
Oncology
Internal medicine
Docetaxel
Cyclophosphamide
Hazard ratio
Regimen
Axillary lymph nodes
Tolerability
Standard treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations